Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab
From Pharmaceutical Executive · · 2 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.